Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

NeoSync

NeoSync?uq=w9if130k
2008 FOUNDED
PRIVATE STATUS
Series D LATEST DEAL TYPE
$13M LATEST DEAL AMOUNT
2 INVESTORS
Description

Developer of personalized therapies designed to treat major mental depressions. The company's personalized therapies use Transcranial Magnetic Stimulation (TMS) which is a non-invasive form of brain stimulation that delivers low energy, alternating magnetic field stimulation in daily 30 minute sessions to gently adjust a depressed brain toward a more normal state, enabling patients to cure major depressive disorders and other diseases of the central nervous system quickly.

Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Therapeutic Devices
Other Industries
Other Healthcare Technology Systems
Other Devices and Supplies
Primary Office
  • 28 Damrell Street
  • Boston, MA
  • United States

+1 (781) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore NeoSync’s full profile, request a free trial.

NeoSync Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC (Series D) 10-Aug-2017 $13M 000.00 Completed Clinical Trials - Phase 3
5. Later Stage VC (Series C) 01-Jan-2016 000.00 000.00 000.00 Completed Startup
4. Later Stage VC (Series C) 21-Jun-2010 00.000 00.000 0000 Completed Startup
3. Early Stage VC (Series B) 10-Mar-2009 00.000 00.000 00.00 Completed Startup
2. Early Stage VC (Series A) 25-Feb-2008 $1.27M $1.27M 00.000 Completed Startup
1. Grant Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

NeoSync Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series D 00,000,000 00.000000 00.00 00.00 00 00.00 00.000
Series C 00,000,000 00.000000 00.00 00.00 00 00.00 00.00
Series B 1,264,722 $0.001000 $0.06 $0.93 $0.93 1x $0.93 3.87%
Series A 2,385,415 $0.001000 0.04% $0.6 $0.6 1x $0.6 7.29%
To view this company’s complete Cap Table, request access »

NeoSync Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Valiance Growth/Expansion Minority 000 0000 000000 0
Medical University of South Carolina Foundation Limited Partner 000 0000 000000 0

NeoSync Executive Team (4)

Name Title Board
Seat
Contact
Info
Kathryn Rumrill Chief Executive Officer, President & Board Member

3 Former Executives

You’re viewing 1 of 4 executives. Get the full list »

NeoSync Board Members (5)

Name Representing Role Since Contact
Info
Jan Pensaert Self Board Member 000 0000
Kathryn Rumrill NeoSync Chief Executive Officer, President & Board Member 000 0000
Lawrence Best Self Chairman 000 0000
Sacha Lainovic NeoSync Board Member 000 0000

1 Former Board Member

You’re viewing 4 of 5 board members. Get the full list »